Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated by YE2023Executing from a strong financial position with cash and cash... | May 8, 2023

Related Keywords

Berlin ,Germany ,Budapest ,Hungary ,United States ,Frankfurt ,Brandenburg ,Hamburg ,Switzerland ,Russia ,Ukraine ,Berndt Modig ,Marcus Maurer ,Morgan Conn ,Emel Ayg ,Wim Souverijns ,Las Vegas ,Community Engagement ,International Accounting Standards Board ,European Academy Of Allergy Clinical Immunology ,Exchange Commission ,Development Rd Expenses ,International Financial Reporting Standards ,Globenewswire Inc ,Drug Administration ,European Union ,University Hospital Frankfurt ,Chief Executive Officer ,Angioedema Workshop ,Chief Business Officer ,Chief Community Engagement ,Commercial Officer ,Clinical Immunology ,Hybrid Congress ,Hereditary Angioedema Attack ,University Hospital ,Hereditary Angioedema Attacks ,Topline Results ,Foreign Private Issuer ,Statement Regarding Forward Looking ,Annual Report ,Beller Head ,Pharvarisnv Stock Exchange ,News ,Information ,Press Release ,Data ,Rom ,Hase , ,Study ,F ,Hvs416 ,Or ,The ,Prophylactic ,Treatment ,Nticipated ,Y ,E2023executing ,Strong ,Financial ,Position ,Ith ,Cash ,Nd Phvs Nl00150005y4 ,